Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
Fifty years ago, the site opened as Cutter Laboratories and produced modest quantities of a single medicine, albumin, distributed domestically.
- Fifty years ago, the site opened as Cutter Laboratories and produced modest quantities of a single medicine, albumin, distributed domestically.
- Its present plasma processing capacity of 12 million liters annually is more than half of the company’s current global capability.
- Acquiring the site from Talecris Biotherapeutics in 2011 turned Grifols into a top-three plasma-sector powerhouse.
- Innovations at Clayton are being replicated today at new Grifols manufacturing sites in Montreal, Canada, and Cairo, Egypt.